Navigation Links
Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
Date:9/17/2012

Tumor biopsies of four patients following intravenous infusion showed four of four patients had local infection of JX-594 in tumor tissue while normal liver tissue was not affected, providing further evidence of JX-594's tumor selectivity and the ability to administer JX-594 intravenously.  Furthermore, after six or 12 weeks, 59 percent of patients had disease control as measured by modified RECIST and 75 percent of patients had objective responses by Choi criteria. 85 percent of patients had disease control by mRECIST and /or Choi response. 

JX-594: A Multi-Mechanistic Approach To Targeting Cancer
JX-594 is a proprietary, engineered oncolytic immunotherapy designed to selectively target and destroy cancer cells through three diverse mechanisms of action: 1) the lysis of cancer cells 2) the stimulation of an immune response against cancer cells, (i.e., active immunotherapy), and 3) the shutdown of the blood supply to tumors. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or intravenously, induces tumor shrinkage and/or necrosis and is well-tolerated (over 160 patients treated to date). Objective tumor responses have been demonstrated in a variety of cancers including liver, colon, kidney, lung cancer and melanoma. JX-594 has had a favorable, predictable and generally mild safety profile to date which includes flu-like symptoms that resolve in 24 to 48 hours.

JX-594 takes advantage of the natural attributes of poxviruses and was engineered to target and destroy solid tumors both systemically and locally.  The vaccinia virus backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program. This strain naturally targets cancer cells due to common genetic abnormalities in cancer cells. JX-594 was engineered to enhance this cancer-selectivity by inactivating its thymidine kinase (TK) gene and encode the immunogenic
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
2. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
3. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
4. Mettler Toledo Presents In-depth Guidance to Comply with New USP Chapters 41 and 1251 on Balances Used for Quantitative Analysis in the Pharma QC Lab
5. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
6. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
7. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
8. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. Grant & Eisenhofer Represents Key Whistleblower in Justice Dept.s $1.04 Billion Civil Settlement with GlaxoSmithKline
11. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- The Lupus Foundation of America and Eli Lilly ... results from UNVEIL: understanding the impact of lupus, a ... and the challenges not only for those living with ... which involved over 1,000 people with lupus and lupus ... aspects of life including family, work, finances, treatment experiences ...
(Date:9/16/2014)... -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY ), ... and novel medicines to physicians and patients at accessible ... Baum will be a presenter at the 5 ... York City.  Mr. Baum will discuss the company,s growth ... ophthalmology. The presentation is scheduled for 10:40 a.m. EST on ...
(Date:9/16/2014)... 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), a ... chronic pain, announced today that it has entered into ... in a series of animal studies for levorphanol, the ... release form of levorphanol.  Gavril Pasternak, MD, PhD, of ... Dr. Pasternak said, "Levorphanol is a unique ...
Breaking Medicine Technology:"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
(Date:9/16/2014)... 15, 2014A prospective study that compared patient-reported outcomes ... bone metastases demonstrates that single fraction radiation therapy ... radiation therapy (MFRT) when pain, function and quality ... today at the American Society for Radiation Oncology,s ... that improvements in patients, pain, function and degree ...
(Date:9/16/2014)... Beginning October 1st 2014, Dallas’ Park Cities Pet ... clients who book a recurring visit schedule, and thus receive ... Most recurring visit clients are ones that book ... include clients whose unique work schedules or lifestyles simply require ... basis. The newly introduced 15-minute visit length will only ...
(Date:9/16/2014)... Founded by former Miami Beach mayoral ... political organization fighting to legalize medical marijuana in Florida. ... After Party recently commissioned a shot-for-shot parody video of ... the movie “Grease.” ( http://youtu.be/zdcvhUgeDRg ) , Called “You’re ... musical parody faithfully recreates the carnival scene made famous ...
(Date:9/16/2014)... September 16, 2014 Florida Hospital announced ... Lightning to extend its partnership and become the Presenting ... as the team’s official health and wellness partner. As ... Hospital will receive a logo and name inclusion on ... two seasons. Florida Hospital has been a sponsorship partner ...
(Date:9/16/2014)... serve of dairy food may reduce the risk of ... foods have not traditionally formed part of the diet. ... by Emeritus Professor Mark Wahlqvist from Monash University,s Department ... Institute, considered the role increased consumption of dairy foods ... longevity. , "In a dominantly Chinese food culture, ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:Miami Beach Politician Drives 1,400 Miles to Texas to Shoot “Grease” Parody Video Supporting the Legalization of Medical Marijuana in Florida 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3Health News:A heart-felt need for dairy food 2
... Brunswick are facing one of the worst gastroenteritis epidemics ... gear, with patients coming// in droves for relief. The ... continue for a few days but seldom endangers life. ... greater Montreal area have reported the viral outbreak. Dr. ...
... nutrient folate through both diet and supplements may have ... a report in the January issue of Archives of ... year 2047, the prevalence of Alzheimer’s disease is expected ... Delaying the onset of this neurodegenerative disease would significantly ...
... fight malaria in Africa has received its first-ever challenge ... pledge// to match dollar for dollar up to $3 ... a disease that kills more than 1 million people ... ‘Nothing But Nets’ campaign, a partnership between the UN ...
... Welcome to another cold season. If you’re like most adults, ... especially preschoolers, have it worse//, getting as many as eight ... Mayo Clinic Women’s HealthSource offers insights on how you can ... ,It’s a virus, not the temperature, that causes colds. ...
... to improve the treatment given to people bitten by snakes or ... ,Africa, Latin America and Asia are the most affected ... it comes to snake bite, the actual number of death is ... intervention. ,According to a WHO release, rabies figures tenth ...
... disease. Yet recent studies have shown that the chance of ... and exercise//, the chances of surviving it, also depend on ... putting around 50,000 pounds behind a study to be carried ... will involve cancer survivors aged above fifty and with a ...
Cached Medicine News:Health News:Higher Folate Levels Linked to Reduced Risk for Alzheimer’s Diseas 2Health News:Yes, Chicken Soup Can Help 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: